​

Summit Therapeutics (SMMT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

SMMT Stock Forecast

Summit Therapeutics (SMMT) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $34.75, with a high of $44.00 and a low of $21.00. This represents a 86.83% increase from the last price of $18.60.

- $9 $18 $27 $36 $45 High: $44 Avg: $34.75 Low: $21 Last Closed Price: $18.6

SMMT Stock Rating

Summit Therapeutics stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (82.35%), 3 Hold (17.65%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 3 14 0 Strong Sell Sell Hold Buy Strong Buy

SMMT Price Target Upside V Benchmarks

TypeNameUpside
StockSummit Therapeutics86.83%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts1110
Avg Price Target$21.00$21.00$35.60
Last Closing Price$18.60$18.60$18.60
Upside/Downside12.90%12.90%91.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25291-113
Aug, 2528--111
Jul, 2537--111
Jun, 2537---10
May, 2536---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 19, 2025Kelsey GoodwinSummit Redstone Partners$21.00$25.71-18.32%12.90%
Apr 28, 2025H.C. Wainwright$44.00$24.1182.50%136.56%
Apr 25, 2025Wells Fargo$30.00$23.4727.82%61.29%
Apr 25, 2025Kelly ShiJefferies$44.00$25.6171.81%136.56%
Mar 26, 2025Yigal NochomovitzSummit Redstone Partners$35.00$19.8975.97%88.17%
Feb 28, 2025Summit Redstone Partners$42.00$20.69103.00%125.81%
Nov 04, 2024Reni BenjaminJMP Securities$32.00$19.9660.32%72.04%
Sep 27, 2024Yigal NochomovitzSummit Redstone Partners$23.00$20.8910.10%23.66%
Sep 25, 2024Brad CaninoStifel Nicolaus$40.00$24.0066.67%115.05%
Sep 16, 2024Mitchell KapoorH.C. Wainwright$45.00$31.9340.93%141.94%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 03, 2025GuggenheimBuyinitialise
Aug 27, 2025H.C. WainwrightBuyBuyhold
Aug 18, 2025Piper SandlerNeutralinitialise
Aug 12, 2025CitigroupBuyBuyhold
Apr 28, 2025H.C. WainwrightBuyBuyhold
Apr 25, 2025JefferiesBuyBuyhold
Mar 26, 2025CitigroupNeutralBuyupgrade
Mar 12, 2025Evercore ISIOutperforminitialise
Feb 28, 2025Goldman SachsBuyinitialise
Dec 11, 2024Wells FargoOverweightinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.76$-0.93$-0.99$-0.31----
Avg Forecast$-0.59$-0.71$-0.47$-0.24$-0.33$-0.48$-0.54$0.17
High Forecast$-0.59$-0.71$-0.47$-0.24$-0.29$-0.38$-0.33$0.17
Low Forecast$-0.59$-0.71$-0.47$-0.24$-0.40$-0.58$-0.75$0.17
Surprise %28.81%30.99%110.64%29.17%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$860.00K$1.81M------
Avg Forecast$14.07M$1.19M$764.45K$9.84M$34.46M$23.63M$178.81M$1.09B
High Forecast$14.07M$1.19M$764.45K$9.84M$34.46M$23.85M$178.81M$1.09B
Low Forecast$14.07M$1.19M$764.45K$9.84M$34.46M$23.42M$178.81M$1.09B
Surprise %-93.89%52.52%------

Net Income Forecast

$-650M $-490M $-330M $-170M $-10M $150M Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-52.70M$-86.15M$-614.93M$-221.31M----
Avg Forecast$-364.11M$-440.95M$-294.21M$-148.97M$-213.66M$-299.12M$-333.36M$104.88M
High Forecast$-364.11M$-440.95M$-294.21M$-146.52M$-182.32M$-238.51M$-204.01M$104.88M
Low Forecast$-364.11M$-440.95M$-294.21M$-151.41M$-245.00M$-359.73M$-462.71M$104.88M
Surprise %-85.53%-80.46%109.01%48.57%----

SMMT Forecast FAQ

Is Summit Therapeutics stock a buy?

Summit Therapeutics stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Summit Therapeutics is a favorable investment for most analysts.

What is Summit Therapeutics's price target?

Summit Therapeutics's price target, set by 17 Wall Street analysts, averages $34.75 over the next 12 months. The price target range spans from $21 at the low end to $44 at the high end, suggesting a potential 86.83% change from the previous closing price of $18.6.

How does Summit Therapeutics stock forecast compare to its benchmarks?

Summit Therapeutics's stock forecast shows a 86.83% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Summit Therapeutics over the past three months?

  • September 2025: 15.38% Strong Buy, 69.23% Buy, 7.69% Hold, 0% Sell, 7.69% Strong Sell.
  • August 2025: 18.18% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 9.09% Strong Sell.
  • July 2025: 27.27% Strong Buy, 63.64% Buy, 0% Hold, 0% Sell, 9.09% Strong Sell.

What is Summit Therapeutics’s EPS forecast?

Summit Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.33, marking a 6.45% increase from the reported $-0.31 in 2024. Estimates for the following years are $-0.48 in 2026, $-0.54 in 2027, and $0.17 in 2028.

What is Summit Therapeutics’s revenue forecast?

Summit Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $34.46M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $23.63M, followed by $178.81M for 2027, and $1.09B for 2028.

What is Summit Therapeutics’s net income forecast?

Summit Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-214M, representing a -3.46% decrease from the reported $-221M in 2024. Projections indicate $-299M in 2026, $-333M in 2027, and $104.88M in 2028.